Summary & Overview
HCPCS A2045: Novashield/Novogen Wound Matrix, Per Square Centimeter
HCPCS Level II code A2045 designates the Novashield or novogen wound matrix product, billed per square centimeter for use in wound management. Biologic wound matrices like this are used to promote tissue regeneration in acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and surgical or traumatic defects. Nationally, the code matters as payers and providers evaluate coverage and coding consistency for advanced wound care products amid growing utilization and cost scrutiny.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines typical payer considerations such as coverage policies, prior authorization tendencies, and coding guidance where available.
Readers will learn the clinical context for A2045, the typical sites of service where the product is applied, and the types of clinical scenarios that may prompt use of a wound matrix billed per square centimeter. The report also summarizes what to expect in payer interactions: policy themes, potential documentation requirements, and common billing practices. Where input data is missing, the report indicates the absence rather than inferring specifics. This summary is intended for a national audience seeking concise, practical information on coding and billing for Novashield/novogen wound matrix products.
Billing Code Overview
HCPCS Level II code A2045 represents the Novashield or novogen wound matrix, billed per square centimeter. This code describes a biologic wound matrix product used in the management of acute and chronic wounds to support tissue regeneration.
Service Type: Wound care product/biologic matrix
Typical Site of Service: Outpatient wound care clinics, hospital outpatient departments, ambulatory surgery centers, and other settings where topical biologic matrices are applied to wounds
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old with a chronic non-healing full-thickness lower-extremity wound (e.g., diabetic foot ulcer or venous stasis ulcer) refractory to standard wound care. After evaluation by a wound care specialist or podiatrist, the wound is debrided and assessed for viable tissue bed and absence of active infection. The clinician measures the defect surface area in square centimeters and determines an appropriate amount of biologic wound matrix is needed. In the procedure visit the provider applies the A2045 product (Novashield/Novogen wound matrix) to the prepared wound bed, secures it with appropriate dressings, and documents product lot numbers, square centimeters used, wound measurements, preparation steps, and post-application plan. Typical follow-up includes scheduled dressing changes, serial debridement if indicated, infection surveillance, and wound measurement at subsequent visits to assess graft incorporation and healing trajectory. The service is commonly performed in outpatient wound clinics, hospital outpatient departments, ambulatory surgery centers, and occasionally inpatient settings for complex patients.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
RT | Right side | Use when product is applied to a wound on the right extremity and laterality reporting is required by the payer |